BB Investment Banking Healthcare
Do you guys know which of the BB offices works on the most number of healthcare, pharma, biotech deals? Especially for GS, MS, and JP? Thanks
Do you guys know which of the BB offices works on the most number of healthcare, pharma, biotech deals? Especially for GS, MS, and JP? Thanks
+161 | How to stop feeling like shit for not making it in IB? | 59 | 2s | |
+118 | If Tik Tok is forced to sell, what banks do you think would be involved in the deal? | 59 | 1h | |
+84 | Updated LA Banking Scene (2024) | 60 | 1h | |
+39 | Ranking banks that went under | 22 | 32m | |
+37 | Burnt Out M&A ASO | 19 | 2s | |
+35 | Relevance of A-Levels for U.K. London recruiting | 24 | 3h | |
+32 | A strategy for SA applicants late to the game like myself | 15 | 22h | |
+27 | Series 79 Help / Tips to Pass The First Attempt | 11 | 2d | |
+27 | Intern Ettiquette | 4 | 1d | |
+23 | What are hours like at BBs in London? | 47 | 1d |
Career Resources
"healthcare" is a giant industry ... saying you work in healthcare is kind of like saying you work in finance. It's sufficient for outsiders, but ambiguous for people familiar with the space ...
I like to break healthcare into the following high-level sectors:
Facilities and providers Medical equipment and devices Bio-tech and pharma
you specifically mentioned bio-tech/pharma, so I ran a quick cap iq screen of closed transactions in this space over the past two years ... I will PM you the results
couldn't figure out how to PM an attachment so i created a topic with the excel file:
http://www.wallstreetoasis.com/forums/re-bb-investment-banking-healthca…
Healthcare Investment Banking BB bank (Originally Posted: 06/21/2012)
Hi, Am new to WSO. Have interned in a top 10 UK bank and am now looking to move to a BB in the healthcare team. Am trying to brush up on healthcare specific valuation methods - specifically for:
1). Pharma (am thinking just normal multiples, dcf etc for big pharma - as ultimately they are large businesses with cash flows) - biotech, maybe some kind of product NPV or probability weighted DCF?
2). Medical devices - also multiples/ dcf. anything specific on this one?
3). Services/ Hospitals (dcf) specific multiples ie. EV/ number of beds?
Generally am just trying to get some colour on how healthcare stuff is valued, and how it differs from the 'textbook' approaches to valuation. Also any comps adjustments that people normally make much appreciated for colour also.
Thanks a lot guys.
they don't really use any unique valuations methods that other groups wouldn't use. They do however use more tools in the toolkit as the healthcare sector is so diverse.
Probability weighted DCFs etc... your kidding. Nobody ever uses something that complicated. Please let me know if you've ever seen one at work.
Please don't talk about things you're not familiar with. Probability-weighted DCFs are definitely used in healthcare banking...specifically for biotech companies.
more than different valuation techniques, i think the primary difference is that healthcare will use different operating metrics when looking at companies in the industry. So, for example, for a private hospital operator, they would look at
ALOS (avg length of stay), in-patient & out-patient volume, procedure volume, etc...among many others.
But that is just one example. Someone in Healthcare Investment Banking, feel free to tell me I'm wrong :-)
as mentioned above, healthcare is an extremely diverse sector - the best way to figure out how to look at these industries is to find equity research if you can. I work for a large public PBM so I see deals range from specialty pharma to DME and other PBMs... and we haven't taken a similar approach to any two deals. take two specialty pharmacies for example, the therapeutic classes of each are obviously not going to be the same, some have preferred agreements with manufacturers, some may be more oncology focused, thus lower margins and some might be focused on slow growth, niche classes. that said, you obviously can't compare apples to apples across this industry. bottom line, there just isn't a standard for the industry.
on the banking side, you really wouldn't be digging too deep into the dcf, but getting an understanding of what the KPIs and drivers of each industry are is important. again, check out equity research for that. i've seen some weird models in my time but nothing to the extent of a probability weighted dcf/npv. i'm not sure that has been done in years, although i know it used to be very popular in biotech.
Thanks a lot guys this is helpful.
Also - does anybody know which 'branches' of healthcare make attractive LBO prospects? Have read about a few LBOs of care/nursing homes (i.e. Terrafirma buying Four Seasons in the UK). and would it be enough at interviews to just touch on the fact that nursing/care homes in this context make decent candidates for LBO because they've got pretty stable cash flows - and then go down the demographic route (ageing population underpinning Revenue growth and FCF generation for debt paydown)?
Thanks a lot.
As with any prospective LBO target, the company would have to have large, predictable cash flows that could support the debt load placed on it by the financial sponsor. Additionally, many players in the health care industry have relatively inelastic demand for their product. As long as those companies have a relatively predicable cost base, they might be attractive as well.
With all the boomers set to retire, long term care/nursing homes seem like they might fit that bill. I have a friend that works in the industry and they are defintely setting their sights on some pretty significant growth.
Thanks cdnbanker. could you very briefly explain to me how this works in practice ie weights applied through different stages of clin. trials and how terminal value is dealt with i.e. (growing perpetuity/ or whether an exit multiple is applied).
If you need equity research reports and industry primers on this industry, I have a few.
That would be extremely helpful mhurricane. Pls could you pm me with them. Much appreciated, thanks.
Biotech is ridonculous if you want quick and large gains, but you need a strong scientific background to distill the proof of concept behind novel compounds. There seems to be alot of guys in healthcare devices and services with business background tho.
Yeah, FDA/regulatory approval can make a stock jump 20+%. I've seen some go up 100%. Earlier this year, VRUS (Pharmasset) was acquired for an 85% premium by Gilead Sciences.
what couchy said it wrong - i used weighted valuation for pharma clients that have drugs in the pipeline pending fda approval. no other way to value them accurately enough if the drug hasn't been commercialized yet. It is the most widely used valuation method in biotech.
I'm sorry. I take back what I said. I interned 3 summers at one of the big healthcare buyside shops and never saw probability weighted dcfs.
With that said, when I went through training, they actually did teach me probabilit weighted valuation and real options valuation. I just never saw one outside of training
But overall in practice we used multiples and LBO / VC method valuation, which is pretty standard across most pe firms.
Well, if by buyside, you are referring to PE, that would make sense. Biotech companies don't exactly make great LBO candidates.
At a very high level, you are right. Probabilities are assigned to each phase of clinical trials, and a cumulative probability of success is calculated and applied to the future cash flows.
In terms of terminal value, it depends. You would consider the same factors you should always consider when building a DCF: What is the most likely exit scenario? If you think the target will be acquired, an exit multiple makes more sense. If you think it will continue to operate as a standalone company, you would use a perpetuity growth rate with a negative growth rate (due to patent expiry). In some cases, you would not consider terminal value at all (if your DCF time horizon is long and covers the entire patent-protected period), since the TV would be negligible anyways.
BB IBD Healthcare Super Day (Originally Posted: 01/13/2015)
Although it does seem obvious to know industry specifics, Healthcare is nonetheless an extremely broad field. I'll be sure to know about the recent M&A Boom, regulation reform, and recent deals, but what exactly should I focus on when attacking this super day? Overall, what industry questions do you think will be asked?
Also, what are the Healthcare valuation methods that I should know about (i.e. Sum-of-the-Parts, etc.) in addition to DCF, Comps, and Prec Trans?
Any advice on what I should bring to the table would be much appreciated.
http://www.wallstreetoasis.com/forums/healthcare-overview-part-1
Probably have your own opinion on where you think the Healthcare/Biotech/BP space is going in the future: Renewed focus on R&D? M&A with a continued focus on inversions?
Probably have an opinion on the costs/benefits of inorganic vs. organic growth so you sound intelligent and that you can display to your interviewer that you have a genuine intellectual interest in the field.
Maybe a stock pitch, you never know.
More importantly, have your behaviorals down pat. Why you want to work at that specific firm, why banking, why healthcare, etc. Make sure you don't bore them with your story and make yourself sound interesting and more hardworking than other candidates.
Thanks man, great advice. Silver Bananaed.
Re: BB Investment Banking Healthcare (Originally Posted: 10/07/2016)
In response to arcticrecon's request for active M&A advisors in the bio-tech/pharma space ... I couldnt figure out how attach the file to PM ...
Advisors in Column T
Consequuntur aperiam omnis qui velit voluptas et unde. Nihil est rerum voluptatibus ab neque. Tempora sapiente ut voluptatem porro voluptatem. Voluptatem impedit sequi est magni minima tempore. Qui molestias fugiat possimus iste. Nam nobis sit voluptas qui nihil dolores harum quae.
Et et ab voluptatem exercitationem ut odio ex. Et nam voluptas deserunt voluptas. Aliquid commodi iste ipsum dicta suscipit reiciendis. Culpa et magnam ipsam laboriosam ex omnis dolorum. Qui iusto vel qui reiciendis. Commodi magni qui in sint consequatur voluptatum.
Temporibus modi repellat quia. Libero hic minima distinctio qui cum expedita. Sequi magnam consectetur dolore ipsum et et quas. Dolorem corrupti ut consequatur saepe est vero molestiae aut.
Id quis consectetur necessitatibus et molestiae vero. Quo ab sed esse voluptatibus tempora. Quis voluptate repudiandae beatae alias iure est est. Qui odit voluptatem quis non mollitia ipsam.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...
Ex praesentium mollitia perferendis quia in eaque. Sit sint ea omnis autem possimus laudantium. Enim sunt eaque ea dolores rerum magni quia voluptas.
Ut maxime qui eum adipisci quo corrupti. Ullam harum expedita quam rem porro adipisci ut. Cupiditate quia aliquid numquam. Voluptatem accusamus repellendus adipisci dolor voluptatem ducimus distinctio.
Odit eveniet accusamus aut tenetur nihil. Delectus molestiae sunt est molestias iure est tenetur aut. Nesciunt ex dolor dolore similique rerum illo rerum. Culpa officiis ducimus non rerum quis omnis tempora. Dicta voluptas inventore ut iusto sunt praesentium aut magni. Earum quos nostrum minus error officiis est quia.